Rigel Pharmaceuticals, Inc. Forecast, price target & analysts
Rigel Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Rigel Pharmaceuticals, Inc. Classifications & Recommendation
Rigel Pharmaceuticals, Inc. Price Target
| Target Price | $56.10 |
| Price | $45.85 |
| Potential |
22.36%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Rigel Pharmaceuticals, Inc. 2027 .
The average Rigel Pharmaceuticals, Inc. target price is $56.10.
This is
22.36%
register free of charge
$89.25
94.66%
register free of charge
$43.43
5.28%
register free of charge
|
|
| A rating was issued by 11 analysts: 8 Analysts recommend Rigel Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rigel Pharmaceuticals, Inc. stock has an average upside potential 2027 of
22.36%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 294.28 | 311.85 |
| 64.15% | 5.97% | |
| EBITDA Margin | 43.46% | 28.08% |
| 194.88% | 35.38% | |
| Net Margin | 124.72% | 17.87% |
| 1,178.41% | 85.67% |
7 Analysts have issued a sales forecast Rigel Pharmaceuticals, Inc. 2026 . The average Rigel Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Rigel Pharmaceuticals, Inc. EBITDA forecast 2026. The average Rigel Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Rigel Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Rigel Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 19.48 | 2.99 |
| 1,867.68% | 84.65% | |
| P/E | 15.34 | |
| EV/Sales | 2.57 |
7 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast for earnings per share. The average Rigel Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rigel Pharmaceuticals, Inc....
Current Rigel Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 02 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 27 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 22 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | May 13 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | May 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 02 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 27 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 22 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
May 13 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
May 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
